List of Excipients in Branded Drug HALOG

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharmaceutical Industries Inc	HALOG	halcinonide cream	10631-094	CETYL ALCOHOL
Sun Pharmaceutical Industries Inc	HALOG	halcinonide cream	10631-094	DIMETHICONE 350
Sun Pharmaceutical Industries Inc	HALOG	halcinonide cream	10631-094	GLYCERYL MONOSTEARATE

HALOG Excipient Strategy and Commercial Opportunities for Halobetasol Propionate

Last updated: September 3, 2026

HALOG is a topical halobetasol propionate product, historically marketed as a 0.05% cream and ointment. Its commercial value is no longer protected by molecule-level exclusivity. The strongest opportunities are differentiated topical vehicles, improved tolerability, lower residue, convenient application, and evidence-based delivery performance.

The most attractive development paths are:

1. A low-residue cream or lotion for large-area plaque psoriasis and eczema.
2. A foam, spray, or solution for scalp and hair-bearing areas.
3. A preservative-minimized or preservative-free formulation for sensitive skin.
4. A vehicle that supports shorter treatment courses while reducing local irritation.
5. A generic or 505(b)(2) product supported by topical bioequivalence and in vitro release data.

What is HALOG and which excipients define its formulation?

HALOG contains halobetasol propionate, a super-high-potency topical corticosteroid. The labeled strength is 0.05%. The product has historically been supplied in cream and ointment dosage forms for corticosteroid-responsive dermatoses, including psoriasis and atopic dermatitis [1].

HALOG cream excipient profile

Public labeling for halobetasol propionate cream products identifies an oil-in-water emulsion system generally containing:

Excipient category	Representative excipients	Commercial function
Emollients and fatty alcohols	Cetyl alcohol, stearyl alcohol	Skin feel, viscosity, emolliency
Emulsifiers	Glyceryl stearate, PEG-100 stearate	Oil-water phase stabilization
Humectant and cosolvent	Propylene glycol	Hydration and drug solubilization
Aqueous phase	Purified water	Continuous phase
Surfactant	Sodium lauryl sulfate or related surfactant	Emulsification and wetting

The cream vehicle is more acceptable than an ointment for daytime use and larger treatment areas. Its liabilities can include sting from propylene glycol or surfactant systems, residue, and phase or viscosity changes during storage.

HALOG ointment excipient profile

Halobetasol ointment products generally use a hydrophobic base consisting primarily of:

• Mineral oil
• White petrolatum
• Related hydrocarbon emollients

Ointment vehicles provide strong occlusion and moisturization. They are useful for thick plaques, severe xerosis, and localized disease. Their disadvantages are greasiness, transfer to clothing, poor cosmetic acceptability, and limited suitability for scalp or intertriginous application.

Why the excipient system matters

Halobetasol is highly potent, so the vehicle affects more than appearance. It influences:

• Drug release from the formulation
• Stratum-corneum partitioning
• Hydration and occlusion
• Local tolerability
• Application adherence
• Area of use
• Risk of inadvertent overuse
• In vitro release and comparative bioequivalence results

A vehicle that increases delivery may also increase local adverse effects. A commercially successful formulation therefore needs a controlled balance between release, skin deposition, cosmetic acceptance, and treatment duration.

What excipient strategy is best for a HALOG follow-on product?

The best strategy is to select the target patient and application site before selecting the vehicle. A single excipient platform will not optimize plaque psoriasis, scalp disease, and sensitive skin.

Strategy 1: Low-residue emulsion cream

A low-residue cream is the most direct opportunity for generic or follow-on development. The target profile is:

• Rapid rub-in
• Low tack
• Minimal whitening
• Low transfer to clothing
• Stable viscosity across temperature conditions
• Reduced stinging
• Acceptable application over large areas

Potential formulation tools include alternative emulsifier systems, lower surfactant loading, nonionic emulsifiers, lightweight esters, and controlled use of glycols. Developers should avoid replacing one irritant with another. Fragrance, essential oils, and unnecessary botanical materials add risk without improving the core product.

The commercial opportunity is greatest where patients reject ointments because of greasiness but need a potency level higher than standard medium-potency corticosteroids.

Strategy 2: Foam or mousse for scalp and hair-bearing areas

Foam is a high-value dosage-form opportunity because it improves access to hair-bearing skin and dries rapidly. A foam can support:

• Scalp psoriasis
• Seborrheic dermatitis with inflammatory components
• Hairline lesions
• Large or difficult-to-reach areas

The excipient strategy may include volatile propellants, alcohol or water systems, surfactants, emollients, and foam stabilizers. The primary risks are stinging, flammability labeling, drying, and packaging compatibility.

A foam product may be more suitable for a 505(b)(2) pathway if the dosage form and vehicle differ materially from the approved cream or ointment. A generic ANDA pathway is more straightforward when the product matches an approved reference dosage form and satisfies applicable pharmaceutical equivalence requirements.

Strategy 3: Lotion or spray for large surface areas

A lotion or spray can create a differentiated product for trunk, limbs, and scalp. The formulation should prioritize:

• Low viscosity
• Metered delivery
• Fast drying
• Uniform coverage
• Reduced hand contact
• Limited dripping

A spray can create dose-uniformity and device-performance challenges. The container-closure system, actuator, plume, priming, tail-off, and delivered dose require characterization. A lotion may offer a simpler regulatory route while preserving much of the convenience benefit.

Potential excipient classes include carbomers, cellulose derivatives, acrylate polymers, light emollients, surfactants, glycols, and pH adjusters. Alcohol content should be controlled because it can increase sting on fissured or inflamed skin.

Strategy 4: Sensitive-skin and preservative-minimized formulation

A formulation designed for patients with barrier impairment can avoid unnecessary irritants. Development priorities include:

• Lower surfactant burden
• Limited or no fragrance
• Reduced propylene glycol exposure where feasible
• Preservative selection based on irritation and sensitization data
• Skin-compatible pH
• Low extractables and leachables risk

A preservative-free multidose product is technically more difficult because microbial control must come from packaging, formulation design, manufacturing controls, or a combination of these. Airless pumps and unit-dose packaging can support this approach but increase cost and packaging complexity.

What formulations are protected by HALOG-related intellectual property?

The historical HALOG formulation itself is unlikely to provide a strong current barrier because halobetasol propionate is an established generic active ingredient and conventional cream and ointment vehicles are widely available.

Commercially meaningful protection would more likely arise from:

• A specific excipient ratio
• A narrow pH or particle-size range
• A stable crystalline form or suspension state
• A foam or aerosol delivery system
• A metered spray package
• A preservative-free multidose container
• A composition that demonstrates improved release or skin deposition
• A method of treating a defined patient population or anatomical site
• A reduced-treatment-frequency regimen supported by clinical data

Patentability of excipient combinations

An excipient combination is not commercially defensible merely because it is new. The patent case is stronger when the formulation shows an unexpected technical result, such as:

• Improved chemical stability
• Lower degradation under accelerated conditions
• Better in vitro release
• Lower irritation
• Improved patient adherence
• Equivalent efficacy with reduced exposure
• Better delivery through hair-bearing skin
• Reduced residue without loss of skin deposition

A claim limited to routine substitution of one emulsifier, preservative, or thickener for another is vulnerable to obviousness challenges. Formulation patents should include comparative data against the reference cream and ointment, not only examples showing that the proposed product is stable.

When does HALOG lose exclusivity and what is the generic-entry risk?

HALOG has already passed the period of ordinary small-molecule market exclusivity. Halobetasol propionate cream and ointment products are available from multiple generic manufacturers, and the commercial market is primarily a generic dermatology market.

Exclusivity category	HALOG position
Active ingredient exclusivity	Expired
Conventional cream or ointment exclusivity	Expired or no longer commercially controlling
Biosimilar exclusivity	Not applicable
Generic competition	Established
Main remaining barriers	Formulation performance, manufacturing, regulatory approval, contracting, and distribution

The key risk is therefore not first generic entry. It is rapid price erosion after approval. A conventional ANDA with no meaningful vehicle differentiation may compete mainly on price.

What is the FDA regulatory status of HALOG and its follow-on products?

HALOG and halobetasol propionate products are prescription topical corticosteroids regulated as drug products. A follow-on developer generally has two primary routes.

ANDA route

An ANDA is appropriate when the proposed product can demonstrate pharmaceutical equivalence and bioequivalence to a relevant reference product. For topical dermatological products, FDA may evaluate:

• Q1 sameness of inactive ingredients
• Q2 sameness of inactive-ingredient amounts
• Comparative physicochemical properties
• Product performance
• In vitro release testing
• In vitro permeation testing where relevant
• Pharmacodynamic or clinical endpoint studies when needed

A formulation that substantially changes the vehicle may create an ANDA risk, particularly if the change affects release, skin permeation, local tolerability, or dosage-form classification.

505(b)(2) route

A 505(b)(2) application can support a materially differentiated product, such as:

• Foam
• Spray
• Novel lotion
• New delivery device
• Modified treatment regimen
• Formulation with a new clinical-use profile

The route may require additional safety, efficacy, or bridging evidence. It can produce stronger differentiation but carries higher development cost and regulatory complexity than a conventional ANDA.

What is the Orange Book status of HALOG?

The Orange Book is the principal U.S. source for approved drug products, therapeutic equivalence evaluations, patents, and regulatory exclusivity information [2]. For a HALOG follow-on strategy, the relevant diligence points are:

1. Identify the exact reference product and dosage form.
2. Confirm whether the listed reference is cream, ointment, lotion, foam, or another presentation.
3. Review current patent listings and regulatory exclusivity.
4. Determine whether any method-of-use patents remain listed.
5. Confirm the applicable therapeutic-equivalence rating for competing products.
6. Review whether a proposed formulation change could require a 505(b)(2) application.

Because HALOG is an older topical corticosteroid brand, the key commercial issue is generally not an active HALOG patent blocking conventional generic entry. It is whether the proposed product can obtain approval and preserve margin in a crowded market.

How strong is the patent estate for an excipient-led HALOG product?

A new formulation patent could be moderate to strong if it combines three elements:

1. A narrow, reproducible composition.
2. A clear manufacturing process that competitors cannot easily design around.
3. Comparative clinical or performance data showing a meaningful benefit.

Stronger claim themes

• Defined polymer or emulsifier system tied to improved stability
• Specific particle-size distribution for suspended halobetasol
• Aerosol or foam composition with controlled delivery
• Packaging system that preserves product integrity
• Reduced-irritation composition supported by human tolerability data
• Method claims directed to scalp or hair-bearing skin
• Lower-frequency dosing supported by clinical outcomes

Weaker claim themes

• Broad use of common emollients
• Routine changes in viscosity
• Generic preservative substitutions
• Conventional cream compositions without unexpected results
• Treatment claims that merely restate established corticosteroid indications

Patent term should be calculated from the earliest effective nonprovisional or international filing date, subject to patent-term adjustment and any applicable regulatory extension. Formulation patents filed today would generally provide a nominal 20-year term from the earliest effective filing date under U.S. law [3].

Which manufacturing and intellectual-property barriers affect commercial launch?

Manufacturing is a meaningful barrier for topical semisolids. Critical process variables include:

• API particle size and crystal form
• Milling or homogenization energy
• Order of phase addition
• Emulsification temperature
• Cooling rate
• Shear profile
• Deaeration
• Fill weight
• Tube or pump compatibility
• Microbial control

Halobetasol is used at a low concentration, making content uniformity and sampling important. A small change in particle size or dispersion can affect release and skin deposition. Scale-up can also change emulsion structure, viscosity, and product appearance.

For foams and sprays, the device is part of the product performance profile. Propellant selection, valve design, actuator geometry, and container compatibility can become practical barriers even where the composition itself is not strongly protected.

What commercial opportunities exist for HALOG excipients?

Opportunity ranking

Product concept	Patient need	Development complexity	Differentiation potential	Commercial assessment
Low-residue cream	Daytime use and larger areas	Moderate	Moderate	Strongest generic-plus opportunity
Lightweight lotion	Trunk and limb coverage	Moderate	Moderate	Attractive if stability and release are controlled
Scalp foam	Hair-bearing areas	High	High	High-value differentiated product
Metered spray	Convenient large-area dosing	High	High	Device and dose-uniformity risk
Ointment with improved spreadability	Thick plaques and xerosis	Low to moderate	Low to moderate	Price-sensitive
Preservative-minimized cream	Sensitive skin	Moderate	Moderate	Useful niche positioning
Combination product	Inflammation plus infection or keratinization	High	High	Greater clinical and regulatory burden

The strongest business case is likely a product that improves the user experience without materially increasing treatment risk. Dermatology products are sensitive to adherence, and a cosmetically acceptable vehicle can support prescription preference even when the active ingredient is generic.

How does HALOG compare with competing topical corticosteroid opportunities?

Halobetasol competes with other high-potency corticosteroids, including clobetasol propionate, betamethasone dipropionate, fluocinonide, and augmented betamethasone formulations.

Attribute	Halobetasol 0.05%	Clobetasol 0.05%	Betamethasone dipropionate	Commercial implication
Potency class	Super-high potency	Super-high potency	High to super-high depending on formulation	Vehicle and labeling matter as much as molecule
Common dosage forms	Cream, ointment, lotion, foam products in market	Cream, ointment, solution, foam, shampoo	Cream, ointment, lotion, gel, spray	Multiple vehicle gaps remain
Generic competition	Established	Established	Established	Molecule-only strategy is weak
Differentiation lever	Vehicle, tolerability, site-specific delivery	Broad dosage-form competition	Formulation breadth and pricing	Halobetasol needs a clear use-case
Biosimilar risk	None	None	None	These are small molecules, not biologics

A halobetasol product must compete against established clobetasol foams, solutions, and shampoos as well as conventional generic creams. A scalp-oriented product therefore needs a clear delivery and tolerability advantage rather than simply a new package.

What patent litigation and Paragraph IV risks affect HALOG?

The primary Paragraph IV risk for a new halobetasol product would arise from patents covering a novel reference product, vehicle, device, or method of use rather than from the old HALOG active ingredient.

Potential disputes could involve:

• Formulation patents
• Foam or aerosol delivery systems
• Device patents
• Skin-deposition methods
• Low-dose or reduced-frequency treatment regimens
• Combination therapy claims
• Patent listings associated with a newer branded halobetasol product

A conventional generic applicant may pursue a Paragraph IV certification if a listed patent is believed invalid, unenforceable, or not infringed. A 30-month stay can affect approval timing when the relevant statutory conditions are met. Settlement agreements may include launch dates, licenses, authorized-generic terms, or restrictions on dosage-form competition.

No biosimilar litigation applies because halobetasol propionate is a chemically synthesized small molecule, not a biologic.

What geographic coverage matters for HALOG excipient commercialization?

The United States offers the clearest opportunity for an ANDA-based product, but excipient and vehicle strategies should be designed for later expansion.

Key markets include:

• United States: ANDA or 505(b)(2), Orange Book and therapeutic-equivalence considerations
• European Union: national or decentralized procedures, with different topical bioequivalence expectations
• Canada: abbreviated new drug submission or applicable hybrid pathway
• Japan: local regulatory and clinical bridging requirements
• Emerging markets: lower price points but potentially less differentiation premium

A formulation using globally available excipients reduces supply risk. Proprietary or specialized polymers may strengthen differentiation but increase qualification, cost, and regional registration complexity.

Key Takeaways

• HALOG is a legacy halobetasol propionate 0.05% topical corticosteroid product with no meaningful molecule-level exclusivity remaining.
• Conventional cream and ointment products face established generic competition and substantial price pressure.
• The best commercial opportunities are low-residue creams, lotions, scalp foams, sprays, and sensitive-skin vehicles.
• Excipients should be selected around patient use conditions, not only formulation convenience.
• Strong patent protection requires defined composition, reproducible manufacturing, and comparative performance data.
• An ANDA is most attractive for a close vehicle match. A 505(b)(2) application is more suitable for a materially new dosage form or delivery system.
• Biosimilar risk does not apply. Paragraph IV risk is more likely to involve newer formulation, device, or method-of-use patents.
• The strongest commercial positioning is improved application and adherence rather than a claim of greater corticosteroid potency.

FAQs

Can propylene glycol be removed from a HALOG formulation?

Yes, but removing propylene glycol may affect drug solubilization, preservation, viscosity, skin feel, and release. The replacement system would require comparative stability and performance testing.

Is a halobetasol foam more commercially attractive than a halobetasol cream?

A foam has greater differentiation potential, particularly for scalp and hair-bearing skin. It also has higher device, manufacturing, flammability, and regulatory complexity.

Can a new HALOG excipient composition qualify for an ANDA?

Possibly, if it remains within the applicable sameness and bioequivalence framework. A materially different vehicle may require a 505(b)(2) application.

Are excipient patents enough to prevent generic competition?

Usually not by themselves. Narrow formulation patents can be designed around unless they are supported by unexpected performance results and manufacturing constraints.

What is the main revenue risk for a new halobetasol product?

The main risk is rapid generic price erosion. A product without a differentiated vehicle, dosage form, device, or reimbursed clinical advantage is likely to compete primarily on acquisition cost.

References

1. U.S. Food and Drug Administration. (n.d.). HALOG: Halobetasol propionate cream and ointment prescribing information. FDA labeling database. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

3. United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation. https://www.uspto.gov/patents/laws/patent-term-adjustment-patent-term-extension

4. U.S. Food and Drug Administration. (2022). Physicochemical and structural (Q3) characterization of topical drug products submitted in ANDAs: Draft guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

5. U.S. Food and Drug Administration. (2022). Topical dermatologic corticosteroids: In vitro release testing and related considerations. FDA guidance and regulatory resources. https://www.fda.gov/drugs/dermatologic-drug-products